# (19) World Intellectual Property Organization International Bureau



# 

# (43) International Publication Date 25 May 2001 (25.05.2001)

### **PCT**

# (10) International Publication Number WO 01/036007 A3

(51) International Patent Classification<sup>7</sup>: A61K 51/12, 31/335, 41/00, A61N 5/10, 5/10 // (A61K 41/00, 31:335)

(21) International Application Number: PCT/CA00/01333

(22) International Filing Date:

14 November 2000 (14.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/165,259 09/712,047 12 November 1999 (12.11.1999) US 13 November 2000 (13.11.2000) US

(71) Applicant (for all designated States except US): AN-GIOTECH PHARMACEUTICALS, INC. [CA/CA]; 6600 N.W. Marine Drive, Vancouver, British Columbia V6T 1Z4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HUNTER, William,L. [CA/CA]; 525 Penticton Street, Vancouver, British

Columbia V5K 3L7 (CA). LIGGINS, Richard [CA/CA]; Apartment 414, 523 Gatensbury Street, Coquitlam, British Columbia V5J 5E8 (CA).


- (74) Agents: NASSIF, Omar, A. et al.; Gowling Lafleur Henderson LLP, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

with international search report

[Continued on next page]

#### (54) Title: COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS



(57) Abstract: Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation, and a cell-cycle inhibitor.



01/036007 A3



(88) Date of publication of the international search report: 4 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

International Application No PCT/CA 00/01333

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K51/12 A61K31/335 //(A61K41/00,31:335) A61N5/10 A61N5/10 A61K41/00

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  $IPC\ 7\ A61K\ A61N$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

	ENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, or the relevant passages	
Y	WO 93 14787 A (UNIV COLUMBIA) 5 August 1993 (1993-08-05)	1-16, 19-211, 213-354
	figures tables	
Y	BECKER A ET AL: "Phase I-II study of simultaneous radiotherapy and paclitaxel (taxol) in a twice a week (TIW) schedule for recurrent squamous cell carcinomas of the head and neck (SCCHN)" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, September 1997 (1997-09), page S193, abstract no. 872, XP004283720 ISSN: 0959-8049 abstract	1-16, 19-211, 213-354
	-/	

X Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.
"A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "8" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
27 November 2001	1 7. 04. 2002
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  DULLAART A.W.M.

International Application No
PCT/CA 00/01333

	PC1/CA 00/01333
	V.
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
ZANELLI G D ET AL: "Paclitaxel as a Radiosensitiser: A Proposed Schedule of Administration Based on In Vitro Data and Pharmacokinetic Calculations" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 3, March 1997 (1997-03), pages 486-492, XP004282474 ISSN: 0959-8049 abstract page 487, left-hand column tables figures	1-16, 19-211, 213-354
FORMENTI C ET AL: "Concurrent paclitaxel and radiation in locally advanced breast cancer" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 34, 30 September 1998 (1998-09-30), page S12, abstract no. 39 XP004285179 ISSN: 0959-8049 abstract	1-16, 19-211, 213-354
LI C ET AL: "POTENTIATION OF OVARIAN OCA-1 TUMOR RADIORESPONSE BY POLY (L-GLUTAMIC ACID)-PACLITAXEL CONJUGATE" INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 48, no. 4, 1 November 2000 (2000-11-01), pages 1119-1126, XP001023465 ISSN: 0360-3016 the whole document	1-16, 19-211, 213-354
MOTE P A ET AL: "PACLITAXEL SENSITIZES MULTIDRUG RESISTANT CELLS TO RADIATION" ANTI-CANCER DRUGS, OXFORD, GB, vol. 7, no. 2, 1 February 1996 (1996-02-01), pages 182-188, XP002074267 ISSN: 0959-4973 page 183, right-hand column, paragraph 2 figures page 187, right-hand column, paragraph CONCLUSIONS -page 188	1-16, 19-211, 213-354
	Radiosensitiser: A Proposed Schedule of Administration Based on In Vitro Data and Pharmacokinetic Calculations" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 3, March 1997 (1997-03), pages 486-492, XP004282474 ISSN: 0959-8049 abstract page 487, left-hand column tables figures  FORMENTI C ET AL: "Concurrent paclitaxel and radiation in locally advanced breast cancer" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 34, 30 September 1998 (1998-09-30), page S12, abstract no. 39 XP004285179 ISSN: 0959-8049 abstract  LI C ET AL: "POTENTIATION OF OVARIAN OCA-1 TUMOR RADIORESPONSE BY POLY (L-GLUTAMIC ACID)-PACLITAXEL CONJUGATE" INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 48, no. 4, 1 November 2000 (2000-11-01), pages 119-1126, XP001023465 ISSN: 0360-3016 the whole document  MOTE P A ET AL: "PACLITAXEL SENSITIZES MULTIDRUG RESISTANT CELLS TO RADIATION" ANTI-CANCER DRUGS, OXFORD, GB, vol. 7, no. 2, 1 February 1996 (1996-02-01), pages 182-188, XP002074267 ISSN: 0959-4973 page 183, right-hand column, paragraph 2 figures page 187, right-hand column, paragraph CONCLUSIONS -page 188

International Application No
PCT/CA 00/01333

C (Continue	tinuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	the relevant passages	Relevant to claim No.	
Υ	MILAS L ET AL: "ENHANCEMENT OF TUMOR RADIORESPONSE OF A MURINE BY PACLITAXEL" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, 1994, pages 3506-3510, XP000882929 ISSN: 0008-5472 abstract page 3307; table 1 page 3308, right-hand column, last paragraph	1-16, 19-211, 213-354	
Υ	WO 95 03036 A (ANGIOGENESIS TECH INC ;ARSENAULT A LARRY (CA); BURT HELEN M (CA);) 2 February 1995 (1995-02-02) example 9	1-16, 19-211, 213-354	
Y	WO 96 25176 A (RENO JOHN M ; KUNZ LAWRENCE L (US); NEORX CORP (US)) 22 August 1996 (1996-08-22) claims 4,8,11,18,27,32,36,45,49,53,57,61	1-16, 19-211, 213-354	
Υ	WO 98 43618 A (NEORX CORP) 8 October 1998 (1998-10-08)	1-16, 19-211, 213-354	
	example 18		
Υ .	KORNOWSKI RAN ET AL: "Slow-release taxol coated GRII stents reduce neointima formation in a porcine coronary in-stent restenosis model."  70TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION; ORLANDO, FLORIDA, USA; NOVEMBER 9-12, 1997, vol. 96, no. 8 SUPPL., 1997, page I341 XP000891206 Circulation 10/21/97, 1997 ISSN: 0009-7322 abstract	1-16, 19-211, 213-354	
Y	HAEHNEL I ET AL: "Local growth inhibitory effect of paclitaxel release by a biodegradable stent coating on vascular smooth muscle cells."  47TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY; ATLANTA, GEORGIA, USA; MARCH 29-APRIL 1, 1998, vol. 31, no. 2 SUPPL. A, February 1998 (1998-02), page 278A XP000877498  Journal of the American College of Cardiology Feb., 1998 ISSN: 0735-1097 abstract	1-16, 19-211, 213-354	

International Application No
PCT/CA 00/01333

ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	1-16,
polymer-coated stents reduce neointima." 70TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION; ORLANDO, FLORIDA, USA; NOVEMBER 9-12, 1997, vol. 96, no. 8 SUPPL., 1997, page I608 XP000891207 Circulation 10/21/97, 1997 ISSN: 0009-7322 abstract	19-211, 213-354
HAEHNEL I ET AL: "Local growth inhibitory effect of paclitaxel released by a biodegradable stent coating on vascular smooth muscle cells."  XIXTH CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY TOGETHER WITH THE 32ND ANNUAL GENERAL MEETING OF THE ASSOCIATION OF EUROPEAN PAEDIATRIC CARDIOLOGISTS; STOCKHOLM, SWEDEN; AUGUST 24-28, 1997, vol. 18, no. ABSTR. SUPPL., 1997, page 460 XP000877497  European Heart Journal 1997 ISSN: 0195-668X abstract	1-16, 19-211, 213-354
MANIFOLD D K ET AL: "Taxol coated stents in oesophageal adenocarcinoma." DIGESTIVE DISEASE WEEK AND THE 99TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION; NEW ORLEANS, LOUISIANA, USA; MAY 16-22, 1998, vol. 114, no. 4 PART 2, 15 April 1998 (1998-04-15), page A27 XP000891205 Gastroenterology April 15, 1998 ISSN: 0016-5085 abstract	1-16, 19-211, 213-354
VOISARD R ET AL: "Paclitaxel-coated biodegradable stents inhibit proliferative activity and severely damage cytoskeletal components of smooth muscle cells from human coronary plaque material in vitro." XXTH CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY; VIENNA, AUSTRIA; AUGUST 22-26, 1998, vol. 19, no. ABST. SUPPL., August 1998 (1998-08), page 376 XP000891208 European Heart Journal Aug., 1998 ISSN: 0195-668X abstract	1-16, 19-211, 213-354
	FARB ANDREW ET AL: "Paclitaxel polymer-coated stents reduce neointima." 70TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION; ORLANDO, FLORIDA, USA; NOVEMBER 9-12, 1997, vol. 96, no. 8 SUPPL., 1997, page 1608 XP000891207 Circulation 10/21/97, 1997 ISSN: 0009-7322 abstract  HAEHNEL I ET AL: "Local growth inhibitory effect of paclitaxel released by a biodegradable stent coating on vascular smooth muscle cells." XIXTH CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY TOGETHER WITH THE 32ND ANNUAL GENERAL MEETING OF THE ASSOCIATION OF EUROPEAN PAEDIATRIC CARDIOLOGISTS; STOCKHOLM, SWEDEN; AUGUST 24-28, 1997, vol. 18, no. ABSTR. SUPPL., 1997, page 460 XP000877497 European Heart Journal 1997 ISSN: 0195-668X abstract  MANIFOLD D K ET AL: "Taxol coated stents in oesophageal adenocarcinoma." DIGESTIVE DISEASE WEEK AND THE 99TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION; NEW ORLEANS, LOUISIANA, USA; MAY 16-22, 1998, vol. 114, no. 4 PART 2, 15 April 1998 (1998-04-15), page A27 XP000891205 Gastroenterology April 15, 1998 ISSN: 0016-5085 abstract  VOISARD R ET AL: "Paclitaxel-coated biodegradable stents inhibit proliferative activity and severely damage cytoskeletal components of smooth muscle cells from human coronary plaque material in vitro." XXTH CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY; VIENNA, AUSTRIA; AUGUST 22-26, 1998, vol. 19, no. ABST. SUPPL., August 1998 (1998-08), page 376 XP000891208 European Heart Journal Aug., 1998 ISSN: 0195-668X abstract

International Application No
PCT/CA 00/01333

0.00	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Calegory		
Y	HAEHNEL IRIS ET AL: "Differential effect of a local paclitaxel release from a biodegradable stent coating on vascular smooth muscle cells and endothelial cells in a coculture model." 48TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY; NEW ORLEANS, LOUISIANA, USA; MARCH 7-10, 1999, vol. 33, no. 2 SUPPL. A, February 1999 (1999-02), page 222A XP000877499 Journal of the American College of Cardiology Feb., 1999 ISSN: 0735-1097 abstract	1-16, 19-211, 213-354
Υ	DE 197 54 870 A (ALT ECKHARD PROF DR) 6 August 1998 (1998-08-06)	1-16, 19-211, 213-354
	claims	

International application No. PCT/CA 00/01333

# INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  Although claims 182-354 are directed to a method of treatment of the human/animal body, a search has been carried out, based on the alleged effects of the device/combination.
2. X Claims Nos.: 1-16, 19-211 and 213-354 in part, and 17, 18 and 212 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  See FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-15, 19-210, 213-354 partially, and 16, 211
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-15,19-210, 213-354 in part, and 16, 211

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the taxane paclitaxel

2. Claims: 1-15,19-210, 213-247, 249-272, 274-277, 279-287, 289-310, 312-329, 331-337, 339-345, 347-353 in part, and 17, 212

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the toposiomerase inhibitor camptothecin or irinotecan

3. Claims: 1-15, 18-210, 213-247, 249-263, 265-329, 331-337, 339-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the alkylating agent dacarbazine

4. Claims: 1-15, 18-210, 213-247, 249-263, 265-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the nitrogen mustard alkylating agent ifosfamide

5. Claims: 1-15, 18-210, 213-247, 249-329, 331-337, 339-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the nitrosurea alkylating agent carmustine or lomustine

6. Claims: 1-15,18-210, 213-239, 241-254, 256-277, 279-299, 301-310, 312-345, 347-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the antimetabolite 5-fluorouracil

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. Claims: 1-15,18-210, 213-254, 256-277, 279-299, 301-310, 312-345, 347-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the antimetabolite methotrexate, or the structurally related folinic acid (leucovorine)

8. Claims: 1-15,18-210, 213-239, 241-254, 256-277, 279-299, 301-345, 347-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the antimetabolite gemcitabine or cytarabine, or the structurally related floxuridine.

9. Claims: 1-15,18-210, 213-229, 231-239, 241-277, 279-299, 301-310, 312-345, 347-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the vinca alkaloid vincristine or its sulfate

10. Claims: 1-15,19-210, 213-229, 231-345, 347-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is the platinum compound cisplatin

11. Claims: 1-15,19-210, 213-229, 231-254, 256-263, 265-287, 289-299, 301-329, 331-337, 339-345, 347-353 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the cell-cycle inhibitor is mitomycin

12. Claims: 1-15,19-210, 213-229, 231-239, 241-263, 265-277, 279-287, 289-345, 347-354 in part

Devices and methods for the combined therapeutic use of radiation and a cell-cycle inhibitor, in which the

FURTHER INFORMATION CONTINUED FROM	PCT/ISA/ 210
cell-cycle inhibitor	is the anthracycline doxorubicin
·	
1	

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-16, 19-211 and 213-354 in part, and 17, 18 and 212

In view of the large number and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that the possibility to perform a meaningful search is severely impaired. Moreover, the pharmacologically active compounds mentioned in present claims 1-16, 19-211 and 213-354 are mainly defined by reference to a desirable characteristic or property, namely their ability to act as a cell-cycle inhibitor. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of compositions containing such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds contained in the compositions prepared in the examples.

Remark: the present objection is raised only in the frameworl of the ifrst invention, as defined under the objection for lack of unity. For the remaining inventions, similar objections are likely to be raised.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Information on patent family members

International Application No
PCT/CA 00/01333

		D 111 11			2.1.
Patent docu cited in search		Publication date		Patent family member(s)	Publication date
WO 93147	87 A	05-08-1993	CA WO AU EP JP US	2128693 A1 9314787 A1 2333892 A 0624096 A1 7506341 T 6080777 A	05-08-1993 05-08-1993 01-09-1993 17-11-1994 13-07-1995 27-06-2000
WO 95030		02-02-1995	ATU AU CA CO DE EPPERS GRANUS SUS	154757 T 6991198 A 693797 B2 7119294 A 2167268 A1 9503036 A1 1130866 A 69403966 D1 69403966 T2 706376 T3 1155689 A2 1155690 A2 1155691 A2 11559974 A1 1155691 A2 1159975 A2 0706376 A1 0797988 A2 2106553 T3 3024833 T3 9503488 T 960226 A 268326 A 5886026 A 5716981 A 5994341 A	15-07-1998 09-07-1998 20-02-1995 02-02-1995 02-02-1995 11-09-1996 31-07-1997 05-02-1998 13-10-1997 21-11-2001 21-11-2001 05-12-2001 21-12-2001 17-04-1996 01-10-1997 01-11-1997 01-11-1997 30-01-1998 08-04-1997 18-03-1996 19-12-1997 23-03-1999 10-02-1998 30-11-1999
WO 962517	'6 A	22-08-1996	AU CA EP JP WO US US US	4985196 A 2212537 A1 0809515 A1 11500635 T 9625176 A1 6358989 B1 6171609 B1 5981568 A 6306421 B1 2002025979 A1	04-09-1996 22-08-1996 03-12-1997 19-01-1999 22-08-1996 19-03-2002 09-01-2001 09-11-1999 23-10-2001 28-02-2002
WO 984361	8 A	08-10-1998	US US BR EP JP WO US US	5981568 A 6306421 B1 9808109 A 0975340 A2 2001521503 T 9843618 A2 6358989 B1 2002025979 A1	09-11-1999 23-10-2001 08-03-2000 02-02-2000 06-11-2001 08-10-1998 19-03-2002 28-02-2002
DE 197548	70 A	06-08-1998	US DE US	5871437 A 19754870 A1 6159142 A	16-02-1999 06-08-1998 12-12-2000